Award
National Cancer Institute 7R01CA194409-10
sEcad as a novel target and therapy for IGF-1R expressing tumors
Recipient
University of Rochester, Rochester, NY
Award Amount
$201,369.00
Ceiling
$201,369.00
Awarded
March 02, 2026
Identifier
7R01CA194409-10
Research project funded by the National Cancer Institute to develop novel antibody-based therapies targeting soluble E-cadherin (sEcad) for IGF-1R expressing tumors, aiming to overcome resistance in breast cancer treatment.
Description
This project investigates the role of soluble E-cadherin (sEcad) as a therapeutic target in breast cancer, focusing on its interaction with IGF-1R and potential for antibody-based inhibition to overcome resistance mechanisms. The research aims to characterize sEcad-IGF-1R interactions, evaluate targeted inhibition of sEcad, and develop antibody-based therapies that may offer a new class of IGF-1R inhibitors.